LIAISON HBeAg

The LIAISON HBeAg assay uses chemiluminescent immunoassay (CLIA) technology for the quantitative determination of e antigen of hepatitis B virus (HBeAg) in human serum or plasma samples. HBeAg quantification may allow follow up of replicative activity/response to treatment (e.g. interferon) (20). The test has to be performed on the LIAISON analyzer family.

Please click below for more information

HEPATITIS AND RETROVIRUS